FDA approved the first generic versions of Levaquin (levofloxacin), an antibiotic approved to treat certain infections in people aged 18 and older.
FDA approved the first generic versions of Levaquin (levofloxacin), an antibiotic approved to treat certain infections in people aged 18 and older.
Generic tablet, oral solution, and injectable solution dosage forms of levofloxacin have been approved. The following 12 manufacturer’s applications for generic levofloxacin have been approved:
•
Akorn
•
Aurobindo Pharma
•
Dr. Reddy’s Laboratories
•
Glenmark Generics
•
Hi-Tech Pharmacal
•
Lupin
•
Mylan
•
Sagent Strides
•
Sandoz
•
Teva
•
Torrent Pharmaceuticals
•
Wockhardt
“This approval provides generic versions of an important class of antibiotics [fluoroquinolones],” said David Belian, spokesperson for the Generic Pharmaceutical Association in Washington, DC. “Levofloxacin injection is used to treat infections such as pneumonia; chronic bronchitis; and sinus, urinary tract, kidney, prostate [a male reproductive gland], and skin infections.
“Levofloxacin injection is also used to prevent anthrax [a serious infection that may be spread on purpose as part of a bioterror attack] in people who may have been exposed to anthrax germs in the air,” added Belian. “Generic versions of this drug provide redundancy in the supply, which could be critical in a bioterror situation.”
All fluoroquinolones have a boxed warning alerting prescribers and patients that these products are associated with an increased risk of tendinitis and tendon rupture. The risk is greater in older people, especially in those older than aged 60, in patients taking corticosteroid drugs, and in those with kidney, heart, or lung transplants. The boxed warning also contains an alert that the drug may worsen muscle weakness in people with myasthenia gravis, a chronic autoimmune neuromuscular disease.
Levofloxacin must be dispensed with a patient Medication Guide that describes the drug’s uses and warnings.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Are PBMs Putting GLP-1 Drugs on Their Formularies?
October 11th 2024PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is uneven. What is needed is more data about whether these drugs can lower overall healthcare costs.
Read More